Brief: Spago Nanomedical Submits Application To Start Tumorad Phase I/IIa Study

Spago Nanomedical AB (publ)

23/05/2023 08:08

May 23 (Reuters) - Spago Nanomedical AB (publ)
 SPAGO.ST :
    * HAS SUBMITTED APPLICATION TO START TUMORAD® CLINICAL PHASE
I/IIA
STUDY
    * APPLICATION TO START STUDY HAS BEEN SENT TO ETHICS
COMMITTEE AND
PATIENT ENROLLMENT IS EXPECTED TO START IN SUMMER 2023

Source text for Eikon:  ID:nMFN8x1lmB 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))